Trial Profile
Randomised Dose Ranging Observer Blind Single Centre Study to Evaluate Safety and Immunogenicity of Adjuvanted and Non-Adjuvanted Influenza H9 Influenza Vaccine in Humans.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jul 2015
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H9N2 (Primary) ; Aluminium phosphate
- Indications Influenza A virus infections
- Focus Pharmacodynamics
- 22 Jul 2009 Actual patient number (353) added as reported by ClinicalTrials.gov.
- 22 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jan 2009 New trial record.